ANDA 215942, held by Teva Pharms Inc. Cabozantinib.
As of Nov 15, 2026, ANDA 215942 (Cabozantinib), held by Teva Pharms Inc, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 27, 2022 | Original application | Tentative approval | None posted |
| Cabozantinib20MG · tablet;oral | Cabozantinib | Rx |
| Cabozantinib40MG · tablet;oral | Cabozantinib | Rx |
| Cabozantinib60MG · tablet;oral | Cabozantinib | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters